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Take home message:  
Diagnostic, treatment and outcome details of 49 COVID-19 patients with concurrent or 
previous tuberculosis from 8 countries show varied clinical profiles. 
 
word count 1,329 
Dear Editor, 
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) 
pandemic has attracted interest because of its global rapid spread, clinical severity, high 
mortality rate, and capacity to overwhelm healthcare systems [1,2]. SARS-CoV-2 
transmission occurs mainly through droplets, although surface contamination contributes and 
debate continues on aerosol transmission [3-5]. 
The disease is usually characterized by initial signs and symptoms [4-9] similar to those of 
related viral infections (e.g., influenza, SARS, Middle East Respiratory Syndrome [MERS]) 
and tuberculosis (TB), although prognosis and complications sometimes differ. Experience 
with concomitant TB and COVID-19 is extremely limited. 
One case-control study of COVID-19 patients with IGRA-confirmed TB infection [10] and a 
single case of TB with COVID-19 were submitted but not yet published in peer-reviewed 
journals [11]. In a recent analysis of 1,217 consecutive respiratory specimens collected from 
COVID-19 patients Mycobacterium tuberculosis was not detected [12]. 
The present study describes the first-ever global cohort of current or former TB patients 
(post-TB treatment sequelae) with COVID-19, recruited by the Global Tuberculosis Network 
(GTN) in 8 countries and 3 continents. No analysis for determinants of outcome was 
attempted. 
The study is nested within the GTN project monitoring adverse drug reactions [13,14] for 
which the coordinating centre has an ethics committee approval, alongside ethics clearance 
from participating centres according to the respective national regulation [13,14]. A specific 
nested database was created in collaboration with the 8 countries reporting patients with TB 
and COVID; the remaining countries did not observe COVID-19 yet in their patients at the 
moment this manuscript was written.  
Continuous variables, if not otherwise specified, are presented as medians (IQR-Interquartile 
ranges). 
Overall, 49 consecutive patients with current or former TB and COVID-19 from 26 centres in 
Belgium (1), Brazil (Porto Alegre, Rio Grande do Sul State; 1), France (12), Italy (17), 
Russia (Moscow Region; 6), Singapore (1), Spain (10) and Switzerland (Vaud Canton; 1) 
were recruited (dataset updated as of April 25
th
, 2020, Table 1).  
The first onset of COVID-19 in the cohort was observed in an Italian patient with TB 
sequelae on March 12
th
, 2020 (symptoms from March 6
th
). 
Of 49 patients, 26 (53.0%) had TB before COVID-19, 14 (28.5%) had COVID-19 first and 9 
(18.3%) had both diseases diagnosed within the same week (4 on the same day).  
Forty-two (85.7%) patients had active TB [median age 45.5 (28.0-63.0) years] and 7 (14.3%) 
had post-TB treatment sequelae [median age: 69.0 (66.0-70.0) years; p-value= 0.01]; the 
patients with TB sequelae (from 5 centres in Italy, Singapore, Spain and Switzerland) were 
cured 8.2 (2.7-44.3) years earlier. 
Overall, 26/49 (53.1%) patients were migrants, 15/48 (31.3%) unemployed, and 2/48 (4.1%) 
health care workers (medical doctor and radiology technician).  
Forty-six (93.9%) patients had confirmed SARS-CoV-2 infection and 3 other patients (6.1%) 
had chest High Resolution Computerized Tomography (HRCT) highly suggestive of COVID-
19 related pneumonia (bilateral ground glass opacities) [15].  
Forty-eight patients had pulmonary TB (one caused by Mycobacterium bovis). 
Thirty-seven patients had drug-susceptible (or were treated with the standard first-line 
regimen for new cases) and eight had drug-resistant TB (and were treated with second-line 
drugs). 
Of the 14 non-clustered patients with COVID-19 diagnosis preceding TB, a child of Gambian 
origin (3 months old) had SARS-CoV-2 identified 3 days before TB diagnosis although TB 
was probably pre-existing (pulmonary and extra-pulmonary TB, meningitis). The child is 
continuing anti-TB treatment and has now recovered from COVID-19. Altogether the 
diagnosis of COVID-19 preceded that of TB by a median (range) time of 4 (2-10) days. 
Those 14 patients, managed in 9 centres (in France, Italy, Russia, Spain) were young [median 
age 33 (26.0-46.0) years]; 11/14 (78.5%) were migrants. 
Of the 19 patients undergoing anti-TB treatment, the diagnosis of COVID-19 was made 
during month 1-2 for 10 (52.6%), month 3-4 for 3 (15.7%), month 4- 6 for 3 (15.7%) and 
after 6 months for 3 (15.7%) patients. 
Signs and symptoms attributed to COVID-19 included (in different combinations) fever 
(32/48, 81.2%), dry cough (27/48, 56.2%) and dyspnoea (17/48, 35.4%). 
Radiological information was available for 48/49 (98.0%) patients: 23 (47.9%) presented 
cavities (Table 1). 
Twenty-one patients manifested a typical HRCT COVID-19 pattern (bilateral ground glass 
opacities), whereas 23 had different patterns at HRCT or chest radiography essentially 
reporting TB-related lesions (e.g., infiltrates, consolidations, cavities, etc.) and 5 were not 
studied during the course of COVID-19 disease. 
Forty- three (87.8%) patients were hospitalized and, provisionally, the overall median (IQR) 
number of hospital admission days was 15 (8-27). Six patients needed non-invasive 
ventilation and 14 oxygen supply. 
Medication for COVID-19 was reported for 28 patients in all countries except Belgium and 
Brazil (which had a single case each): 22 (78.6%) received, in different combinations, 
hydroxychloroquine, 12 (42.9%) received an anti-HIV protease inhibitor (i.e. 
lopinavir/ritonavir, darunavir/cobicistat), 7 (25.0%) patients received azithromycin, and 1 
(3.6%) patient received other drugs (i.e. enoxaparin and N-acetyl-cysteine, NAC). Seventeen 
(60.8%) patients received a monotherapy (i.e. 11 hydroxychloroquine, 5 lopinavir/ritonavir, 
and 1 azithromycin), 9 (32.1%) received a combination of two drugs (i.e. 5 
hydroxychloroquine and protease inhibitor; 4 hydroxychloroquine plus azithromycin), 2 
(7.1%) received ≥3 drugs (i.e. 1 hydroxychloroquine, lopinavir/ritonavir and azithromycin; 1 
hydroxychloroquine, lopinavir/ritonavir and azithromycin, enoxaparine and NAC).  
The case fatality rate was high (6/49, 12.3%); 5/6 were >60 years old and all of them had ≥1 
co-morbidities. Given the small number of deaths, larger studies are necessary. 
This preliminary analysis suggests that: 
1) In 19/49 (38.8%) patients COVID-19 appeared during anti-TB treatment and limited 
or no protection against COVID-19 might have favoured SARS-CoV-2 infection 
(which affected two healthcare workers). 
2) The diagnosis of TB and COVID-19 was done simultaneously or within 7 days in 9 
patients, posing differential diagnosis challenges, suggesting that clinical assessments 
to investigate COVID-19 (e.g. clinical picture, HRCT) facilitated the identification of 
(a probably pre-existing) TB. Any contribution of COVID-19 to TB pathogenesis 
cannot be excluded or confirmed.  
3) Although the diagnosis of COVID-19 preceded that of TB in 14 patients, larger 
studies are needed to understand any role played by SARS-CoV-2 in the progression 
of TB infection to disease. Given that up to a quarter of the population in some 
regions of the work are latently infected, SARS-CoV-2 infection might boost the 
development of active TB in the coming months [10]. As we do not include 
individuals with latent TB infection followed-up over time, we cannot report on the 
potential contribution of COVID-19 towards development of active disease. Probably, 
an overlap of signs/symptoms of COVID-19 and TB occurred and COVID-19 was 
diagnosed earlier because of a higher index of suspicion while TB may have been 
there since before. Or, differently, COVID brought to clinical evaluation/diagnostic 
assessment TB patients at an earlier stage of disease before the occurrence of TB-
related symptoms.  
4) In 7 cases COVID-19 occurred in patients with TB sequelae. They were older than 
patients under anti-TB treatment and presented higher (although not statistically 
significant) mortality. All but one had co-morbidities (4 Chronic Obstructive 
Pulmonary Disease; 1 HIV co-infection plus liver and kidney diseases, hypertension 
and cancer present in different combinations). They presented unilateral or bilateral 
radiological sequelae of previous infiltrates (4 patients) or cavities (3 patients).  
Larger numbers are necessary to further understand the role played by TB sequelae. 
5) The impact on the healthcare system (e.g., days of admission, intensive care unit beds, 
etc.) was relevant, and will deserve further evaluation. 
6) The information on BCG (Bacillus Calmette-Guérin) vaccination is modest (30 
patients with information, 19 previously vaccinated in all 8 countries) and no 
significant elements can be provided to the ongoing debate on its protective role. 
7) We presently have no data on drug-drug interactions. 
This is, to our knowledge, the first published cohort of patients with active TB and COVID-
19. Our study represents a ‘snapshot’ of a cohort of patients at different stages of disease. No 
attempt was made to obtain representation of the larger universe of patients with both 
diseases and the small sample size precludes an analysis of risk factors. We cannot exclude 
that some findings have a casual origin. 
The information available on the patients recently admitted was accurate, but some details on 
previous TB were incomplete, and some examinations were not performed either because the 
patients refused or the patients’ condition was too severe. Although case reporting is 
comprehensive in the countries/regions covered by GTN, the study reflects the initial stages 
of the COVID-19 epidemic only, and representative longitudinal observations will be 
necessary to evaluate the interactions between COVID-19 and TB. 
We believe that this descriptive research can motivate larger studies to enable analyses of 
interactions and determinants of outcomes in patients with both diseases. The study will 
continue to follow-up the patients and accrue more records. We therefore invite interested 
clinicians and programmes to contact the corresponding author and help improve the 
understanding of how to optimize care for these patients. 
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Table 1. Demographic, epidemiological and clinical characteristics of a cohort of 49^ 
tuberculosis patients with COVID-19 disease. 
Variable 
 
Number/total number 
(%); 
Denominator 
corresponds to total 
number of patients for 
whom data are 
available 
 
Age median [interquartile range] 48 [32-69] 
Male  40/49 (81.6%) 
Migrant status 26/49 (53.1%)                   
Occupation 
Employed  14/48 (29.2%) 
Unemployed 15/48 (31.3%) 
Retired 14/48 (29.2%) 
Student 5/48 (10.4%) 
BCG vaccination 19/30 (63.3%) 
COPD/Asthma 8/47 (17.0%) 
Diabetes Mellitus 8/49 (16.3%)  
HIV infection 6/48 (12.5%) 
Renal failure 5/49 (10.2%) 
Liver disease 7/49 (14.3%) 
Alcohol abuse
a
 10/49 (20.4%) 
Smoking
b
 20/49 (40.8%) 
Drug abuse 4/47 (8.5%)  
TUBERCULOSIS  
Previous history of TB 13/46 (28.3%) 
Site 
Pulmonary TB only 36/49 (73.5%) 
Extrapulmonary TB only 1/49 (2.0%) 
Pulmonary TB/ Extrapulmonary TB(>1 site possible) 12/49 (24.5%) 
Site of extrapulmonary TB 
Bone  2/13 (15.4%) 
Lymphadenitis 2/13 (15.4%) 
Pleural  2/13 (15.4%) 
Central Nervous System  1/13 (7.7%) 
Laryngeal  1/13 (7.7%) 
Gastrointestinal  1/13 (7.7%) 
Peritonitis+ Lymphadenitis+ Pleural + Bone  1/13 (7.7%) 
Genitourinary + Lymphadenitis 1/13 (7.7%) 
Central Nervous System + Lymphadenitis 1/13 (7.7%) 
Bone  + Joint  + Spondylodiscitis (T5-T11) + 
Paravertebral abscesses 
1/13 (7.7%) 
Radiological involvement 
Unilateral cavitary lesions 10/48 (20.8%) 
Bilateral cavitary lesions 13/48 (27.1%) 
Bilateral infiltrates (no cavities) 9/48 (18.8%) 
Unilateral infiltrates 16/48 (33.3%) 
Microbiology  
Sputum culture confirmation 22/49 (44.9%) (+ 8 
sputum culture ongoing) 
NAAT confirmation 13/49 (26.5%) 
Sputum smear positive 9/49 (18.4%) 
Not available 5/49 (10.2%) 
Drug resistance 
Resistant  8/45 (17.8%) (4 MDR-
TB) 
Sensitive 37/45 (82.2%) 
Treatment outcome 
Cured 6/49 (12.2%) 
Completed 1/49 (2.0%) 
On treatment 37/49 (75.5%) 
Died* 5/49 (10.2%) 
Lost to follow-up 0 
Failure 0 
COVID-19  
Symptoms 
Asymptomatic 5/48 (10.4%) 
Symptomatic 43/48 (89.6%) 
Imaging  
Typical (bilateral ground glass opacities) HRCT 
picture 
21/44 (47.7%) 
Treatment outcome 
Resolved 18/49 (36.7%) 
Still on treatment 25/49 (51.0%) 
Died (at any date)* 6/49 (12.3%) 
Abbreviations: SARS-CoV-2=severe acute respiratory syndrome coronavirus 2 TB= tuberculosis; 
BCG=Bacillus Calmette-Guérin; COPD= chronic obstructive pulmonary disease; a: ≥14 drinks per 
week in men or ≥7 drinks per week in women; b: current or ex-smoker;  NAAT= Nuclear Acid 
Amplification Test; MDR-TB= multidrug-resistant tuberculosis.  
* According to the criteria for cohort analysis of treatment results the patients died during anti-TB 
treatment are 5 but the total number of deaths is 6 as one patient with post-TB treatment sequelae died 
after being cured for TB. 
 
 
